Showing posts with label infectious disease diagnostics. Show all posts
Showing posts with label infectious disease diagnostics. Show all posts

Monday, 28 September 2020

Infectious Disease Diagnostics Market Worth 19.35 Billion USD by 2022 | CAGR of 5.6%

 Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.

Hepatitis diagnostics market formed the largest share. Around 70% to 90% of the people in these regions (below 40 years of age) are reportedly suffering from the disease and around 8% to 20% are carriers of this virus. Another factor contributing to the growth of this market is the increasing adoption of advanced technologies for the diagnosis of hepatitis B.

According to the new market research report by MarketsandMarkets, The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.

Download PDF Brochure:  www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589 


Increased accessibility and the increasing number of IDD tests conducted are the key drivers for this segment. Globally, the volume of IDD tests is increasing mainly due to the rising geriatric population; increasing prevalence of infectious diseases; increased variety of reagents available and analytical techniques employed; and the continuous launch of newer, faster, and more reliable products.

Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.

On the basis of disease type, the infectious disease diagnostics (IDD) market is segmented into a wide range of diseases. Hospital acquired infections (HAI) segment to record the highest CAGR during the forecast period. Growth in HAI segment can be attributed to the rising burden of MRSA infections, the increasing number of new products launched in the market, and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assay, Xpert MRSA NxG, and ARIES C. difficile Assay that are based on PCR technology

North America to account for the largest market size during the forecast period.

North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

Request for Sample Pages: www.marketsandmarkets.com/requestsampleNew.asp?id=116764589 

Key Market Players : 

Abbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific

Monday, 3 August 2020

Infectious Disease Diagnostics Market | Technology (Immunodiagnostics, PCR, NGS)

According to the new market research report “Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) – Global Forecast to 2022” published by MarketsandMarkets™

The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.


What Drives the Market?

1. Increasing global prevalence of infectious diseases
2. Shift in focus from centralized laboratories to decentralized point-of-care testing
3. Growth in funding for research on infectious disease diagnostics

The global prevalence of infectious diseases such as influenza, HPV, hepatitis, HIV, and tuberculosis is considerably high in spite of significant improvements in sanitation practices and medicine. Many of the currently available diagnostic techniques are slow, involve complex procedures, and lack specific identification of causative agents.

Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=116764589

By product and service, assays, kits and reagents segment to record the highest CAGR during the forecast period

Increased accessibility and the increasing number of IDD tests conducted are the key drivers for this segment. Globally, the volume of IDD tests is increasing mainly due to the rising geriatric population; increasing prevalence of infectious diseases; increased variety of reagents available and analytical techniques employed; and the continuous launch of newer, faster, and more reliable products.

Roche, Bio-Rad, and bioMérieux are some of the major players in the infectious disease diagnostics market for assays, kits, & reagents.

On the basis of disease type, the infectious disease diagnostics (IDD) market is segmented into a wide range of diseases. Hospital acquired infections (HAI) segment to record the highest CAGR during the forecast period. Growth in HAI segment can be attributed to the rising burden of MRSA infections, the increasing number of new products launched in the market, and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assay, Xpert MRSA NxG, and ARIES C. difficile Assay that are based on PCR technology

Early buyers will receive 10% customization on reports – https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=116764589

The geographical regions mapped in the report are:
1. North America
2. Europe
3. Asia-Pacific
4. Rest of the World (RoW)

North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

Some key players mentioned in the research report are:

Abbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific

Critical questions the report answers:

  • Where will all these developments take the industry in the long term?
  • What are the upcoming trends for the infectious disease diagnostics market?
  • Which segment provides the most opportunity for growth?
  • Who are the leading vendors operating in this market?
  • What are the opportunities for new market entrants?

Request for Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

Tuesday, 7 July 2020

Infectious Disease Diagnostics Market | North America Market is Expected to Grow at the Fastest Rate

According to the new market research report “ Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) - Global Forecast”, published by MarketsandMarkets™

Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.


What Drives the Market?

1. Increasing global prevalence of infectious diseases
2. Shift in focus from centralized laboratories to decentralized point-of-care testing
3. Growth in funding for research on infectious disease diagnostics

The global prevalence of infectious diseases such as influenza, HPV, hepatitis, HIV, and tuberculosis is considerably high in spite of significant improvements in sanitation practices and medicine. Many of the currently available diagnostic techniques are slow, involve complex procedures, and lack specific identification of causative agents.

Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

On the basis of disease type, the infectious disease diagnostics (IDD) market is segmented into a wide range of diseases. Hospital acquired infections (HAI) segment to record the highest CAGR during the forecast period. Growth in HAI segment can be attributed to the rising burden of MRSA infections, the increasing number of new products launched in the market, and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assay, Xpert MRSA NxG, and ARIES C. difficile Assay that are based on PCR technology

Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.

The geographical regions mapped in the report are:
1. North America
2. Europe
3. Asia-Pacific
4. Rest of the World (RoW)

North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

Some key players mentioned in the research report are:

Abbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific

Get Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

Thursday, 4 June 2020

Infectious Disease Diagnostics Market Worth $19.35 Billion by 2022 | North America Market is Expected to Grow at the Fastest Rate

Growth in Infectious Disease Diagnostics Market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.

What the Market Looks Like?
  • The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to   reach $19.35 Billion in 2022, at a CAGR of 5.6%.
North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.
 
On the basis of disease type, the infectious disease diagnostics (IDD) market is segmented into a wide range of diseases. Hospital acquired infections (HAI) segment to record the highest CAGR during the forecast period. Growth in HAI segment can be attributed to the rising burden of MRSA infections, the increasing number of new products launched in the market, and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assay, Xpert MRSA NxG, and ARIES C. difficile Assay that are based on PCR technology

What Drives the Market?

The growth of the global market for infectious disease diagnostics market is primarily influenced by the following factors:


1. Increasing Global Prevalence of Infectious Diseases
2. Shift in Focus From Centralized Laboratories to Decentralized Point-Of-Care Testing
3. Growth in Funding for Research on Infectious Disease Diagnostics

Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.

Read more about infectious disease diagnostics market @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

The geographical regions mapped in the report are:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

Some key players mentioned in the research report are:

Abbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific

Wednesday, 27 May 2020

Infectious Disease Diagnostics Market and Increasing Global Prevalence of Infectious Diseases

 Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) - Global Forecast to 2022

The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

                  

The Infectious Disease Diagnostics Market is Segmented on:

1. Product & Service
2. Disease Type
3. Technology
4. End User

By product and service, assays, kits and reagents segment to record the highest CAGR during the forecast period

Increased accessibility and the increasing number of IDD tests conducted are the key drivers for this segment. Globally, the volume of IDD tests is increasing mainly due to the rising geriatric population; increasing prevalence of infectious diseases; increased variety of reagents available and analytical techniques employed; and the continuous launch of newer, faster, and more reliable products.

By technology, DNA sequencing & next-generation sequencing (NGS) segment to record the highest CAGR during the forecast period


Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.

Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

Critical questions the report answers:

  • Where will all these developments take the industry in the long term?
  • What are the upcoming trends for the infectious disease diagnostics market?
  • Which segment provides the most opportunity for growth?
  • Who are the leading vendors operating in this market?
  • What are the opportunities for new market entrants?
Key Market Players

The prominent players in this market areAbbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific



Friday, 15 November 2019

Useful Analysis from Experts on Infectious Disease Diagnostics Market



The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589


Global Market Segmentation:

The market is broadly segmented into assays, kits, & reagents; instruments; and services & software based on product & service. The assays, kits, & reagents segment accounted for the largest share of the global market and is expected to register the highest CAGR during the forecast period. The increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages are the key factors driving the IDD assays, kits, & reagents market.

Based on the disease type, the market is segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases. The hepatitis diagnostics segment accounted for the largest share of the global market in 2017. The dominant share of this segment can be attributed to the rising prevalence of hepatitis B and C, the availability of a large number of hepatitis diagnostic tests, and increasing number of HIV/Hepatitis co-infections.

The infectious disease diagnostics market is segmented into major seven technologies, namely, immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays, and other technologies. In 2017, the immunodiagnostics segment accounted for the largest share of the global market. The large share of this segment can be attributed to the increasing use of immunoassays in POC infectious disease testing, development of novel tests, rising trend of automation, and increasing awareness about health and fitness.

On the basis of end user, the global market is segmented into hospitals/clinical laboratories, reference laboratories, physician offices, academic/research institutes, and other end users. In 2017, the hospitals/clinical laboratories segment accounted for the largest share of the global market. Also, this segment is expected to grow at the highest CAGR during the forecast period due to the large number of diagnostic tests carried out in hospitals.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

What Drives the Market?

Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics

Geographical Growth Analysis:
North America accounted for the largest share of the global market. This large share can be attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

Some of The Major Players In infectious disease diagnostics :
1. Proteus Digital Health, Inc. (U.S.)
2. Omada Health Inc. (U.S.)
3. WellDoc Inc. (U.S.)
4. Livongo Health (U.S.)
5 Noom Inc. (U.S.)
6. Ginger.io Inc. (U.S.), etc.